BACKGROUND: Although liver disease commonly causes morbidity and mortality among human immunodeficiency virus (HIV)-infected individuals, data are limited on its prevalence in HIV monoinfection. We used the aspartate aminotransferase-to-platelet ratio index (APRI) as a surrogate marker of hepatic fibrosis to characterize liver disease in the Multicenter AIDS Cohort Study. METHODS: Men were categorized based on their HIV and viral hepatitis status: uninfected (n = 1170), HIV monoinfected (n = 509), viral hepatitis monoinfected (n = 74), and HIV-viral hepatitis coinfected (n = 66). RESULTS: The median APRI in the HIV-monoinfected group was similar to that in the hepatitis-monoinfected group (0.42 vs 0.43; P > .05), higher than in the uninfected group (0.42 vs 0.27; P < .001) but lower than in the coinfected group (0.42 vs 1.0; P < .001). On multivariable analysis, HIV infection (1.39-fold increase [FI]; P < .001), viral hepatitis infection (1.52-FI; P < .001), and the interaction between HIV and viral hepatitis infections were independently associated with a higher APRI (1.57-FI; P < .001). Among the HIV-infected men, viral hepatitis coinfection (2.34-FI; P < .001), HIV RNA ≥100 000 copies/mL (1.26-FI; P = .007), and CD4 count ≤200 cells/mL (1.23-FI; P = .022) were independently associated with a higher APRI. CONCLUSIONS: HIV and viral hepatitis are independently associated with an increased APRI. Further studies are needed to understand the biological basis for the association between HIV and liver disease.
BACKGROUND: Although liver disease commonly causes morbidity and mortality among human immunodeficiency virus (HIV)-infected individuals, data are limited on its prevalence in HIV monoinfection. We used the aspartate aminotransferase-to-platelet ratio index (APRI) as a surrogate marker of hepatic fibrosis to characterize liver disease in the Multicenter AIDS Cohort Study. METHODS:Men were categorized based on their HIV and viral hepatitis status: uninfected (n = 1170), HIV monoinfected (n = 509), viral hepatitis monoinfected (n = 74), and HIV-viral hepatitis coinfected (n = 66). RESULTS: The median APRI in the HIV-monoinfected group was similar to that in the hepatitis-monoinfected group (0.42 vs 0.43; P > .05), higher than in the uninfected group (0.42 vs 0.27; P < .001) but lower than in the coinfected group (0.42 vs 1.0; P < .001). On multivariable analysis, HIV infection (1.39-fold increase [FI]; P < .001), viral hepatitis infection (1.52-FI; P < .001), and the interaction between HIV and viral hepatitis infections were independently associated with a higher APRI (1.57-FI; P < .001). Among the HIV-infectedmen, viral hepatitis coinfection (2.34-FI; P < .001), HIV RNA ≥100 000 copies/mL (1.26-FI; P = .007), and CD4 count ≤200 cells/mL (1.23-FI; P = .022) were independently associated with a higher APRI. CONCLUSIONS:HIV and viral hepatitis are independently associated with an increased APRI. Further studies are needed to understand the biological basis for the association between HIV and liver disease.
Authors: J F Colin; D Cazals-Hatem; M A Loriot; M Martinot-Peignoux; B N Pham; A Auperin; C Degott; J P Benhamou; S Erlinger; D Valla; P Marcellin Journal: Hepatology Date: 1999-04 Impact factor: 17.425
Authors: Chun-Tao Wai; Joel K Greenson; Robert J Fontana; John D Kalbfleisch; Jorge A Marrero; Hari S Conjeevaram; Anna S-F Lok Journal: Hepatology Date: 2003-08 Impact factor: 17.425
Authors: P Meraviglia; M Schiavini; A Castagna; P Viganò; T Bini; S Landonio; A Danise; M C Moioli; E Angeli; M Bongiovanni; H Hasson; P Duca; A Cargnel Journal: HIV Med Date: 2004-09 Impact factor: 3.180
Authors: Stacey R Vlahakis; Angelina Villasis-Keever; Timothy S Gomez; Gary D Bren; Carlos V Paya Journal: J Infect Dis Date: 2003-11-18 Impact factor: 5.226
Authors: Michael Reid; Yifei Ma; Rebecca Scherzer; Jennifer C Price; Audrey L French; Michael W Plankey; Carl Grunfeld; Phyllis C Tien Journal: AIDS Date: 2017-01-28 Impact factor: 4.177
Authors: Joseph K Lim; Janet P Tate; Shawn L Fultz; Joseph L Goulet; Joseph Conigliaro; Kendall J Bryant; Adam J Gordon; Cynthia Gibert; David Rimland; Matthew Bidwell Goetz; Marina B Klein; David A Fiellin; Amy C Justice; Vincent Lo Re Journal: Clin Infect Dis Date: 2014-02-25 Impact factor: 9.079
Authors: Michael J Vinikoor; Lloyd Mulenga; Alice Siyunda; Kalo Musukuma; Roma Chilengi; Carolyn Bolton Moore; Benjamin H Chi; Mary-Ann Davies; Matthias Egger; Gilles Wandeler Journal: Trop Med Int Health Date: 2016-08-30 Impact factor: 2.622
Authors: Michael J Vinikoor; Edford Sinkala; Aggrey Mweemba; Arianna Zanolini; Lloyd Mulenga; Izukanji Sikazwe; Michael W Fried; Joseph J Eron; Gilles Wandeler; Benjamin H Chi Journal: Liver Int Date: 2015-01-22 Impact factor: 5.828
Authors: Sophia Swanson; Yifei Ma; Rebecca Scherzer; Greg Huhn; Audrey L French; Michael W Plankey; Carl Grunfeld; William M Rosenberg; Marion G Peters; Phyllis C Tien Journal: J Infect Dis Date: 2015-11-29 Impact factor: 5.226
Authors: George K Siberry; Rachel A Cohen; D Robert Harris; Maria Leticia Santos Cruz; Ricardo Oliveira; Mario F Peixoto; Maria Celia Cervi; Rohan Hazra; Jorge A Pinto Journal: Pediatr Infect Dis J Date: 2014-02 Impact factor: 2.129
Authors: H Nina Kim; Robin Nance; Stephen Van Rompaey; Joseph C Delaney; Heidi M Crane; Edward R Cachay; Elvin Geng; Stephen L Boswell; Benigno Rodriguez; Joseph J Eron; Michael Saag; Richard D Moore; Mari M Kitahata Journal: J Acquir Immune Defic Syndr Date: 2016-08-01 Impact factor: 3.731